Microcap Ledger Matinas BioPharma Holdings, Inc. $MTNB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Bedminster, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 14,692,796 [10-Q 2026-08-13]
What the company doesAI summary of filing
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies based on its lipid nanocrystal platform delivery technology. The company's lead product candidate is MAT2203, an oral formulation of amphotericin B for treating life-threatening invasive fungal infections; MAT2203 completed a Phase 2 trial and is positioned for a Phase 3 registration trial, though development is currently paused pending partnership or additional capital. The company does not yet generate revenue from product sales. Following an 80% workforce reduction in October 2024, Matinas is seeking development and commercialization partners or evaluating strategic alternatives including potential asset sales or dissolution. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$3.25M | −$3.44M | $761.0K | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$10.35M | −$7.01M | $4.00M | [10-K 2026-03-31] |
| FY ended Dec 2024 | — | −$24.25M | −$15.88M | $7.28M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$1.72M
- Cash runway Estimate
- ~1.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 5,086,985 | [10-Q 2024-11-13] |
| 2025-04-15 | 5,086,985 | [10-K 2025-04-15] |
| 2025-05-15 | 5,086,985 | [10-Q 2025-05-15] |
| 2025-08-12 | 5,086,985 | [10-Q 2025-08-14] |
| 2025-11-06 | 6,406,191 | [10-Q 2025-11-10] |
| 2026-03-26 | 6,406,191 | [10-K 2026-03-31] |
| 2026-05-08 | 6,406,191 | [10-Q 2026-05-08] |
| 2026-08-10 | 14,692,796 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-06-16; no effectiveness notice found in EDGAR [S-3 2026-06-16]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-04. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-04 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-04] |
| 2026-06-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-26] |
| 2026-04-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-03] |
| 2025-01-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-10] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-10 | Stern Adam K | other | 344,710 | $0.35 | [4 2026-08-13] |
| 2026-07-10 | Stern Adam K | other | 630,335 | $0.35 | [4 2026-08-13] |
| 2025-10-31 | Stern Adam K | other | 92,100 | $0.64 | [4 2026-08-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-09-16 | 8-K | Other events |
| 2026-09-04 | 8-K | Listing notice or transfer; Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-24 | 8-K | Material agreement terminated |
| 2026-07-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-13 | 8-K | Material agreement entered; Unregistered sale of equity; Change to security holder rights |
| 2026-06-26 | 8-K | Listing notice or transfer; Other events |
| 2026-06-22 | 424B7 | Prospectus or prospectus supplement |
| 2026-06-16 | S-3 | Registration statement |
| 2026-05-08 | 10-Q | Quarterly report |
Alerts for $MTNB
Email me when Matinas BioPharma Holdings, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.